Collaborations and cross-licensing are the key strategies adopted by a majority of players in the global antibody library technologies market. In a new publication titled “Antibody Library Technologies Market: Global Industry Analysis and Forecast, 2016–2024,” the analysts at XploreMR have observed that antibodies being a most successful biotechnology drug class, pharmaceutical companies are striving to add antibodies to their pipeline in order to alleviate patent cliff. While studying the various market segments the expert team of analysts have noted that North America represents the most lucrative regional market, followed by Europe and APAC. Another key observation is that despite phage display being the fastest growing technology, yeast display system is becoming a choice of technology due to the improved quality of MAB obtained through it. This report provides useful information regarding transitions in the business value proposition of key players. For instance, MorphoSys AG has set a goal to build the most valuable biopharmaceutical pipeline in the biotech industry and in line with this, the company is shifting its focus from technology licensing to drug development.
Major deals in the global antibody library technologies market
- In August 2016, Italy-based biotechnology company Philogen entered into a collaboration agreement with Janssen Biotech Inc. – a Johnson & Johnson Company
- In April 2016, Adimab LLC announced the signing of a collaboration agreement with Takeda Pharmaceutical Company Ltd.
- In January 2016, Adimab LLC licensed its proprietary antibody libraries to Merck KGaA, under which Merck will internalize the Adimab technology and apply it broadly across its R&D programs
Why are Antibody Libraries not widely perceived as research reagents?
Although the antibodies selected by in vitro method are very powerful, the technology is not widely perceived as a valuable research reagent. The primary reason is a patent situation, which limits the use of this technology to high margin therapeutic markets. In contrast, classical hybridoma technology was never patented and thus achieved widespread acceptance in academics as well as for commercial purposes within a short period of time. However, some of the phage display patents are about to expire in the next few years while some have already expired, which may result in wide acceptance of the new technology. This technology is largely unnoticed by the research community due to the dominance of traditional hybridoma technology in most of the markets. For instance, some of the commercially available monoclonal antibodies are actually obtained by phage display screening but are reformatted to resemble murine antibodies.
Global Market Study on Antibody Library Technologies: Phage Display Segment by Technology to Register a CAGR of 5.0% During 2016–2024Buy Now
Custom Market Research Services
xploreMR offers custom market reserch services that help clients to get information on their business scenario required where syndicated solutions are not enough
Why Choose XploreMR
Our analysts go above and beyond to answer your specific queries. We are with you throughout the entire journey – from initial discussion to post-purchase.
Country-wise Analysis & Forecasting
As we track markets at country-level, we are able to offer hard-to-find market intelligence in both developed and emerging countries.
High Quality At Competitive Pricing
We believe high quality market research shouldn’t be out of reach for businesses. Our competitively-priced market research reports ensure businesses of all sizes have access to quality information
A recent market study published by XploreMR on the cell culture media bags market including global industry analysis for 2015-2019 & opportunity assessment for 2020-2030, delivers a comprehensive ...
Sinus Therapeutic Drugs Market Analysis 2020-2030 A recent market study published by XploreMR on the Sinus Therapeutic Drugs Market including global industry analysis for 2015-2019 & opportunity ...